Cambios en el perfil inmunohistoquímico pre y post neoadyuvancia en cáncer de mama. Experiencia del Hospital Británico de Buenos Aires / Changes in biomarkers in pre and post neoadjuvant breast carcinoma

Introducción: actualmente la quimioterapia neoadyuvante ha ampliado sus indicaciones en el tratamiento del cáncer de mama. Se observó variabilidad en la expresión de biomarcadores postneoadyuvancia que pueden acompañarse de cambios en el tratamiento adyuvane. Objetivos: el objetivo principal fue evaluar la variabilidad de biomarcadores pre y post neoadyuvancia. Los objetivos secundarios fueron determinar qué subtipo inmunohistoquímico tumoral alcanzó más frecuentemente la respuesta patológica completa (PCR), si la variación en los biomarcadores derivó en un cambio de inmunofenotipo y posteriormente en una modificación del tratamiento adyuvante. Material y método: se realizó un estudio retrospectivo observacional de las pacientes con diagnóstico de cáncer de mama que realizaron neoadyuvancia en el servicio de mastología del Hospital Británico de Buenos Aires entre enero 2009 y junio 2019. Resultados: se incluyeron 127 pacientes. La variabilidad observada para receptores de estrógeno (RE) fue de 7,6%, resultando no estadísticamente significativo. Para receptores de progesterona (RP) fue de 28,3% y para HER2 fue de 13,1%, estos cambios fueron estadísticamente significativos. El inmunofenotipo tumoral que alcanzó más frecuentemente la PCR fue el grup RH-/HER2+. Hubo cambios en el inmunofenotipo tumoral en 17 casos y modificaciones al tratamiento adyuvante en 5 de estos. Conclusiones: en este estudio observamos una variabilidad estadísticamente significativa en la expresión de RP y HER2 posteriormente al tratamiento neoadyuvante. En cambio la variabilidad de RE no es estadísticamente significativa. Estos cambios determinan modificaciones en el inmunofenotipo tumoral y en el tratamiento adyuvante en el 29,4% de estos casos (5,4% del total de la serie), justificando la reevaluación de biomarcadores en la pieza quirúrgica. La tasa de PCR fue del 27,6%. Se observó con mayor frecuencia en el grupo RH-/HER2+ alcanzando un valor de 83,3%.

Introduction: nowadays neoadjuvant chemotherapy has extended its indications in breast cáncer treatment. A variantion in tumoral biomark expression has been observed after neoadjuvant treatment, this can be accompanied by a modification in adjuvant treatment. Objetives: to evaluate the variability in biomarkers before and after neoajuvant chemotherapy. To observe which inmunehistochemical subtype reache most frequently pathologic complete response, to determine if changes in biomarkers derived in a change in adjuvant treatment. Material and method: this is an observational retrospective study on patients with breast cáncer diagnosis who underwent neoadjuvant chemotherapy in Buenos Aires British Hospital between 2009 and june 2019. Results: the variability observed for estrogen receptor was 7,6%, not statistically significant; for progesterone receptor was 28,3%, for HER2 13,1%, these modifications were statistically significant. Pathologic complete response was achieved most frequently by RH-/HER2+ carcinomas. We observed changes in subtype in 17 cases ant modifications to adjuvant treatment in 5 cases. Conclusions: in this study we observed modifications in progesterone receptors and HER2 expression before and after neoadjuvant treatment, these were statistically significan. The modifications in estrogen receptors expression were not statistically significant. They led to changes in tumoral subtype and in the adjuvant treatment in 29,4% of the cases. This justifies retesting tumoral biomarkers after the neadjuvant setting. The rate of pathologic complete response was of 27,6%, mainly given by RH-/HER2 + tumors.

Progress in the research of application of hot springs in health care and adjuvant treatment of diseases / 上海预防医学

Hot spring is a kind of precious natural water resource formed under specific geological conditions and obtained by natural gushing or artificial drilling, and is rich in minerals and trace elements peculiar to deep strata. Hot spring bathing is a physical therapy with a long history. An increasing number of studies have shown the positive effects of hot spring bathing in maintaining health and the auxiliary treatment and rehabilitation of chronic diseases. This paper reviews the distribution, classification and application history of hot springs, and further explores the research on the effect of hot springs on the improvement of sub-health status and the adjuvant treatment of chronic diseases such as skin diseases, cardiovascular diseases and joint diseases, so as to provide reference for further understanding of the physiotherapy value of hot spring bathing and boost its role in the development of big health industries.

Adjuvant treatment strategy after curative resection for hepatocellular carcinoma / 医学前沿

Hepatic resection represents the first-line treatment for patients with resectable hepatocellular carcinoma (HCC). However, the 5-year recurrence rates of HCC after surgery have been reported to range from 50% to 70%. In this review, we evaluated the available evidence for the efficiency of adjuvant treatments to prevent HCC recurrence after curative liver resection. Antiviral therapy has potential advantages in terms of reducing the recurrence rate and improving the overall survival (OS) and/or disease-free survival of patients with hepatitis-related HCC. Postoperative adjuvant transarterial chemoembolization can significantly reduce the intrahepatic recurrence rate and improve OS, especially for patients with a high risk of recurrence. The efficacy of molecular targeted drugs as an adjuvant therapy deserves further study. Adjuvant adoptive immunotherapy can significantly improve the clinical prognosis in the early stage. Randomized controlled trial (RCT) studies evaluating adjuvant immune checkpoint inhibitors are ongoing, and the results are highly expected. Adjuvant hepatic artery infusion chemotherapy might be beneficial in patients with vascular invasion. Huaier granule, a traditional Chinese medicine, has been proved to be effective in prolonging the recurrence-free survival and reducing extrahepatic recurrence. The efficiency of other adjuvant treatments needs to be further confirmed by large RCT studies.

Pterigión recidivante y sus alternativas terapéuticas / Recurrent pterygium and its therapeutic alternatives

RESUMEN El pterigión se trata de un crecimiento fibrovascular de morfología triangular que se extiende desde la conjuntiva hacia la córnea. Está clasificado dentro de las degeneraciones no involutivas o tumoraciones epiteliales benignas corneales y se presenta en el 10,2 por ciento de la población. El tratamiento quirúrgico es el más indicado, y tiene una tasa de recidiva independientemente de la técnica quirúrgica utilizada del 10,7 por ciento; esta tasa de recidiva se evidencia por la neovascularización y el tejido cicatrizal antes de los dos meses después de la cirugía. Lo anterior ha incentivado la investigación de nuevos tratamientos que disminuyan esta complicación, por lo que el objetivo de esta revisión bibliográfica fue la búsqueda de alternativas terapéuticas para el pterigión recidivante. Se realizó una búsqueda automatizada sobre el tema, utilizando la plataforma Infomed, cuya información fue resumida para la elaboración del informe final. Concluimos que existen diferentes tratamientos adyuvantes para disminuir la tasa de recurrencia, y es necesario realizar estudios donde se determine el tiempo y la frecuencia en la aplicación de estos para obtener resultados más efectivos en su uso(AU)

ABSTRACT Pterygium is a fibrovascular growth of triangular shape that extends from the conjunctiva to the cornea. It has been classified as a noninvolutionary degeneration or benign corneal epithelial tumor which affects 10.2 percent of the population. The treatment most commonly indicated is surgery, which has a recurrence rate of 10.7 percent, irrespective of the surgical technique used. Recurrence takes the form of neovascularization and scar tissue within two months after surgery. This has fostered research into new treatments to reduce this complication. The objective of the present bibliographic review was precisely to search for therapeutic alternatives for recurrent pterygium. An automated search was conducted about the topic on the platform Infomed. Data were summarized to write the final report. We concluded that there are several adjuvant treatments to reduce recurrence, and it is necessary to carry out studies determining the time and frequency of their application to obtain more effective results(AU)

Ejercicio físico como tratamiento adyuvante de los trastornos mentales. Una revisión narrativa / Physical exercise as an adjuvant treatment of mental disorders. A narrative review

El ejercicio físico puede ser una herramienta importante para el manejo de personas con enfermedades psiquiátricas, puesto que un notable número de estudios longitudinales y transversales ha demostrado que el mismo se constituye en una estrategia preventiva y en un enfoque adyuvante del tratamiento de los trastornos mentales. En ese sentido, se ha evidenciado que las formas más efectivas de ejercicio físico son los ejercicios aeróbicos (tales como caminar, trotar, andar en bicicleta, nadar, entre otros) y los de fortalecimiento. El objetivo de este artículo es presentar una actualización general acerca del ejercicio físico como tratamiento adyuvante de los trastornos mentales. Esta es una revisión narrativa, no sistemática, centrada en literatura primaria seleccionada de una búsqueda en PubMed, SciELO y LILACS. Los términos clave que se utilizaron fueron los siguientes: "ejercicio físico y salud mental", "fisioterapia y salud mental", "ejercicio físico y trastornos mentales" y "ejercicio físico y psiquiatría". Se complementaron estos artículos con libros y capítulos de libros, resaltando hallazgos duplicados. Todos los miembros del equipo de investigación participaron en la revisión de la literatura. Aunque existen excelentes estudios y revisiones que analizan detalladamente el papel del ejercicio físico en el tratamiento específico de algunos trastornos mentales, se consideró que se necesitaba una revisión más general para brindar orientación a médicos psiquiatras y a fisioterapeutas en este campo de integración de la salud física y mental.

Physical exercise can be an important part of the management of people with psychiatric illnesses, since a considerable number of longitudinal and cross-sectional studies has shown that it constitutes a preventive strategy and an adjuvant approach to the treatment of mental disorders. In that sense, it has been demonstrated that the most effective forms of physical exercise are aerobic exercises (such as walking, jogging, cycling, swimming, among others) and strengthening. The aim of this article is to present a general update about physical exercise as an adjuvant treatment of mental disorders. This is a narrative review, not systematic, focused on primary literature selected from a search in PubMed, SciELO and LILACS. The key terms used were: "physical exercise and mental health", "physiotherapy and mental health", "physical exercise and mental disorders" and "physical exercise and psychiatry." These articles were supplemented with books and book chapters, highlighting duplicate findings. All members of the research team participated in the review of the literature. Although there are excellent studies and reviews that analyze in detail the role of physical exercise in the specific treatment of some mental disorders, it was considered that a more general revision was needed to provide guidance to psychiatrists and physiotherapists in this field of integration of physical and mental health.

Observaciones críticas en torno al ganglio centinela en el cáncer colorrectal / Critical observations about the sentinel lymph node in colorectal cancer

Introducción: La identificación del ganglio centinela durante el tratamiento quirúrgico del cáncer colorrectal puede ayudar a la correcta estadificación posoperatoria y trascender a la quimioterapia adyuvante en el seguimiento a fin de mejorar la supervivencia de estos enfermos. Objetivo: Identificar las técnicas utilizadas para detectar el ganglio centinela mediante acceso convencional o laparoscópico: tinción o radiotrazador, ex vivo o in vivo así como su influencia en la estadificación posoperatoria y en el tratamiento adyuvante correlacionado con la evolución del cáncer de colon. Material y Métodos: Revisión documental en formato electrónico e impreso de publicaciones actualizadas sobre el tema. Desarrollo: El estudio de los linfáticos supone el factor pronóstico más importante en el cáncer colorrectal sin metástasis. La detección del ganglio centinela es la técnica que mejor predice el estado ganglionar de un paciente y permite realizar estudios intensivos que mejoran la estadificación. Conclusiones: El estudio del ganglio centinela es una práctica reproducible sin aumento significativo del tiempo y costos. En el seguimiento de los enfermos clasificados N0 con ganglio centinela positivo parece haber tendencia a un porcentaje mayor de recidivas, lo que podría trascender a cambios en las pautas de tratamiento adyuvante en aras de mejorar la supervivencia(AU)

Introduction: The identification of the sentinel lymph node during surgical treatment of colorectal cancer can help the correct postoperative staging and go beyond adjuvant chemotherapy in the follow-up of patients with the aim to improve survival of these sick people. Objective: To identify the techniques used to detect the sentinel lymph node through either conventional or laparoscopic approach: staining or radiotracer ex vivo or in vivo, as well as its influence in postoperative staging and the adjuvant treatment correlated with the evolution of colon cancer. Material and Methods: Document review of up-to-date publications about the topic in both electronic and printed formats. Development:The study of lymphatics is considered the most important prognostic factor in the colorectal cancer without metastases. The detection of the sentinel node is the technique that best predicts the lymph node status in a patient, and allows to conduct intensive studies to improve staging. Conclusions:The study of the sentinel lymph node is a reproducible practice without a significant increase in time and costs. The follow-up of patients classified as NO with a positive sentinel lymph node seems to have a tendency to a higher percentage of relapses, which could go beyond changes in the adjuvant treatment guidelines aimed at improving survival(AU)

The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04) / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: We aimed to assess prognostic value of metastatic pelvic lymph node (mPLN) in early-stage cervical cancer treated with radical surgery followed by postoperative chemoradiotherapy. Also, we sought to define a high-risk group using prognosticators for recurrence. MATERIALS AND METHODS: A multicenter retrospective study was conducted using the data from 13 Korean institutions from 2000 to 2010. A total of 249 IB-IIA patients with high-risk factors were included. We evaluated distant metastasis-free survival (DMFS) and disease-free survival (DFS) in relation to clinicopathologic factors including pNstage, number of mPLN, lymph node (LN)ratio (number of positive LN/number of harvested LN), and log odds of mPLNs (log(number of positive LN+0.5/number of negative LN+0.5)). RESULTS: In univariate analysis, histology (squamous cell carcinoma [SqCC] vs. others), lymphovascular invasion (LVI), number of mPLNs (≤ 3 vs. > 3), LN ratio (≤ 17% vs. > 17%), and log odds of mPLNs (≤ -0.58 vs. > -0.58) were significant prognosticators for DMFS and DFS. Resection margin involvement only affected DFS. No significant survival difference was observed between pN0 patients and patients with 1-3 mPLNs. Multivariate analysis revealed that mPLN > 3, LVI, and non-SqCC were unfavorable index for both DMFS (p 3 in early-stage cervical cancer affects DMFS and DFS. A scoring system using mPLNs > 3, LVI, and non-SqCC could stratify risk groups of recurrence in surgically resected early-stage cervix cancer with high-risk factors.

The clinical discussion on diagnostic and treatment progress of metastatic spinal adrenal pheochromocytoma / 中华内分泌代谢杂志

Metastatic spinal adrenal pheochromocytoma is such a rare disease that its diagnosis is complicated and the treatment scheme has not reached a consensus at the international level. We should take the clinical manifestations, accessory examination, pathological diagnosis and gene tests into a full consideration to improve the accuracy of diagnosis and to choose reasonable treatment to improve the prognosis. The aim of this paper was to summarize the clinical characteristics, diagnostic basis, and treatment protocols of this disease, which may help to promote recognition of metastatic spinal adrenal pheochromocytoma.

Úlcera do pé diabético: manejo clínico adjuvante / Diabetic foot ulcers: clinical adjuvant therapy

Objetivos: A úlcera do pé diabético é uma complicação comum do Diabetes Mellitus associada a altos custos e longos prazos de tratamento. Sendo assim, é fundamental conhecer terapias adjuvantes que podem melhorar os desfechos desses pacientes. Métodos: Foi realizada uma busca na base MEDLINE sobre terapias clínicas adjuvantes para úlceras do pé diabético. Resultados: Após a seleção de acordo com os critérios de inclusão e exclusão e excluindo artigos duplicados, cinco artigos foram selecionados. Conclusões: A terapia padrão deve continuar sendo utilizada, mas a incorporação de outras opções clínicas de manejo deve ser considerada na prática clínica.

Aims: Diabetic foot ulcer (DFU) is a common complication of Diabetes Mellitus associated with high costs and long treatments. Therefore, it is essential to know clinical adjuvant therapies that can improve the outcomes of these patients. Methods: We searched MEDLINE for articles on adjuvant therapies for DFU. Results: After scanning for the inclusion and exclusion criteria and excluding duplicates, five articles were selected Conclusion: Although the standard of care should still be used, the incorporation of other clinical management options must be considered in clinical practice.

Characteristics and adjuvant medical treatment for elderly women with breast cancer / 中国肿瘤临床

The optimal treatment of elderly women with breast cancer still faces many difficulties. Life expectancy, comorbidity, and functional status influence clinical decision and survival. Standard adjuvant medical treatments should not be withheld from healthy older patients with reasonable life expectancies. In this study, adjuvant medical treatment literatures for elderly breast cancer patients, including endocrine therapy, chemotherapy, and HER2-targeted therapy, were reviewed, focusing on efficacy and toxicity of drugs for elderly women.

Study of Different Adjuvant Treatment Regimens as a Complement to Surgery in Patients with Carcinoma Anorectum.

Background: In the present study we have done a retrospective as well as prospective studies of patients with carcinoma anorectum undergoing abdominoperineal resection with special emphasis on the role of adjuvant treatment regimens as a complement to surgery. Methods: 75 patients operated for APR were studied retrospectively and 25 patients operated for the same were studied prospectively. Results: It was observed that colorectal cancer is the most common malignancy of the gastrointestinal tract. Rectum remains the most common site affected by it. Carcinoma anal canal is about one tenth as common as rectal cancer. Adjuvant treatment after surgery was studied with respect to the indications, the schedules followed and the subsequent complications. Conclusion: It was concluded that adjuvant treatment, in the form of Radiotherapy and Chemotherapy, has a definitive role in, both locally advanced Carcinoma Anorectum and for Dukes' C stage but it has its own complications which need to be addressed. Nigro's chemoradiation regimen has become the first choice for carcinoma anal canal, ahead of APR.

Clinical Observation of Shenqi Jiangtang Granule in the Adjuvant Treatment of Type 2 Diabetes Knee Arthri-tis / 中国药房

OBJECTIVE:To observe the efficacy and safety of Shenqi jiangtang granule in the adjuvant treatment of type 2 dia-betes knee arthritis. METHODS:62 patients with type 2 diabetes knee arthritis were randomly divided into control group(31 cas-es) and observation group (31 cases). Control group received hypoglycemic and basic treatment for arthritis,including diet con-trol,exercise therapy and health education,as well as 0.25 g Metformin hydrochloride tablet with a meal,3 times a day + 50 mg Acarbose tablet with a meal,3 times a day,chewing;patients with arthritis pain 100 mg Aspirin enteric-coated tablet after a meal, once a day (chewing or breaking apart was prohibited). Observation group additionally received 3 g Shenqi jiangtang granule half an hour before a meal with 50 ml warm water,3 times a day. The treatment course for both groups was 6 months. Clinical effica-cy,and fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG),glycated hemoglobin(HbA1c),interleukin-1β(IL-1β),IL-6 before and after treatment,and the incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically significant(P0.05). After treatment,FPG,2 h PG,HbA1c,IL-1β and IL-6 in 2 groups were significantly lower than before,and observation group was lower than control group,the differences were statistically significant(P0.05). CONCLUSIONS:Based on conventional treatment,Shenqi jiangtang granule shows obvious efficacy in the adjuvant treatment of type 2 diabetes knee arthritis.,it can reduce blood glucose and inflammation cy-tokine levels,mild symptoms of adverse reactions.

Efficacy Observation of TCM in the Adjuvant Treatment of Asthma and Allergic Rhinitis / 中国药房

OBJECTIVE:To observe the clinical efficacy and complications of TCM in the adjuvant treatment of asthma and allergic rhinitis. METHODS:160 patients with asthma and allergic rhinitis were divided into control group and observation group according to the visiting order of odd or even,80 cases in each group. Control group received basic western medicine,such as lo-ratadine and budesonide used for allergic rhinitis,salmeterol/fluticasone and leukotriene for asthma;observation group additionally received TCM(inline treatment + external treatment),the treatment course was 3 months. Clinical efficacy and complications in 2 groups were compared. RESULTS:The observation group had 2 cases of fall-off patients,and the control group had 3 cases. The total effective rate in observation group was 97.43%,which was higher than control group(74.03%),the difference was statistical-ly significant (P<0.05). The incidence of complications in observation group was 8.97%,which was lower than control group (19.48%),the difference was statistically significant(P<0.05). CONCLUSIONS:TCM can obviously relieve clinical symptoms, improve efficacy and reduce the incidence of complications in the adjuvant treatment of patients with asthma and allergic rhinitis.

Effect Observation of Adjuvant Treatment of Xuebijing Injection for Severe Acute Pancreatitis / 中国药房

OBJECTIVE:To observe therapeutic efficacy of adjuvant treatment of Xuebijing injection for severe acute pancreati-tis. METHODS:80 cases of severe acute pancreatitis were randomly divided into control group and observation group with 40 cas-es in each group. Control group was given symptomatic and supportive treatment,and observation group was additionally given in-travenous injection of Xuebijing injection 100 ml,twice a day,on the basis of control group. The levels of TNF-α,IL-6 and hs-CRP,organ failure were compared between 2 groups before and after treatment. RESULTS:There was no statistical significance in the levels of TNF-α,IL-6 and hs-CRP in 2 groups before treatment(P>0.05);after treatment,the levels of TNF-α,IL-6 and hs-CRP in observation group was significantly lower than control group and before treatment,with statistical significance (P<0.05). The proportion of renal function,respiration function and circulating failure in observation group were significantly lower than in control group,with statistical significance (P<0.05). CONCLUSIONS:Adjuvant treatment of Xuebijing injection for se-vere acute pancreatitis can significantly reduce the level of inflammation in the body and reduce organ damage.

Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study

PURPOSE: Although several clinical trials have proven the efficacy of adjuvant S-1 treatment in gastric cancers, it is still unclear which patients receive the most benefit. In this study, we prospectively recruited patients with locally advanced gastric cancer who had undergone curative resection followed by adjuvant S-1 administration to investigate which factors affect the outcomes. MATERIALS AND METHODS: Between July 2010 and October 2011, we enrolled 49 patients who underwent curative resection for stage II or III gastric cancer and who subsequently received adjuvant S-1 treatment for 1 year. RESULTS: Twenty-nine patients (59.2%) continued S-1 treatment for 1 year, and 12 patients (24.5%) experienced recurrent disease during the follow-up period. Patients with continuation of S-1 for 1 year had significantly increased rates of disease-free survival (P<0.001) and overall survival (P=0.001) relative to the patients who discontinued S-1 during year 1. Multivariate analysis indicated poor outcomes for patients with stage III disease and those who discontinued S-1 treatment. Excluding patients who discontinued S-1 due to cancer progression (n=7), adjuvant treatment with S-1 still demonstrated a significant difference in the disease-free survival rate between the patients who continued treatment and those who discontinued it (P=0.020). CONCLUSIONS: S-1 is tolerated as adjuvant treatment in gastric cancer patients. However, discontinuing S-1 treatment may be an unfavorable factor in the prevention of recurrence. S-1 adjuvant treatment should be continued for 1 year if possible through the proper management of toxicities.

Treatment outcome and prognostic factors in intermediate risk stage I endometrial carcinoma.

Introducton: The aim of this study was to evaluate the clinical characteristics, post-surgery adjuvant treatment approach and posttreatment disease course in patients with intermediate risk stage I endometrium cancer and also to assess the effects of known prognostic factors on this group of patients. Patients and Methods: A total of 148 patients followed up postoperatively or after adjuvant treatment between 1996 and 2007 were evaluated retrospectively. Median follow-up duration was 67 months (range: 7-166). Among the study population 14.9% had Ib and 83.1% had stage Ic disease. 72 were treated by external beam radiotherapy (EBRT), 7 by intracavitary radiotherapy (ICRT), 65 by external + intracavitary radiotherapy (EBRT + ICRT), and one by chemoradiotherapy (CRT). Results: Vaginal vault is found to be the most common site of recurrences. Five and 10-year local control (LC) rates were 96.6% and 95.9%, respectively, while 5 and 10-year distant control (DC) rates were 94.6% and 91.9%, respectively. One, 5 and 10-year overall survival rates (OS) were 99.3%, 87.6% and 71.2%, respectively, while 1, 5 and 10-year progression-free survival rates (PFS) were 97.3%, 87.6% and 71.2%, respectively. Univariate analysis has revealed that prognostic factors as age (P = 0.0001), menopausal status (P = 0.049) and EBRT duration (P = 0.003) statistically significantly affected OS; while age (P = 0.0001) and EBRT duration (P = 0.006) affected PFS. Multivariate analysis has revealed that only age (P = 0.001) (P = 0.0001) and ERT duration (P = 0.021) (P = 0.027) affected both OS and PFS. Conclusion: LC and OS rates are high in the intermediate risk group. Age over 60 years and EBRT duration of 35 days and over both have negative effects on outcome in this group.

Meta-analysis and systematic review:adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma / 中国生化药物杂志

Objective To evaluate the efficacy and safety of adjuvant IFN therapy for viral hepatitis-related hepatocellular carcinoma(HCC)after treatment with surgical resection or transarterial chemoembolization(TACE).Methods Controlled trials of adjuvant treatment with IFN for patients with HCC published between 2000 and 2012 were searched electronically in MEDLINE,PubMed,Cochrane Library,and EMBASE databases.According to the heterogeneity of the studies,two different models-the fixed-effect model and the random-effect model-were applied to analyze the results. Results Ten trials were screened according to inclusion and exclusion standards.Eight randomized,controlled trials and two non-randomized,controlled trials were included.These ten trials with a total of 1 ,029 subjects were eventually involved in the meta-analysis;528 HCC patients were treated with adjuvant treatment with IFN and 501 patients with placebo.Compared to the control group,the recurrence rates of HCC in IFN group were significantly lower CR=0.66;95% CI=0.50 to 0.86;P=0.02),especially after TACE treatment according to subgroup analysis(OR=0.73;95%CI=0.52 to 1.01;P=0.06 for surgical resection;and OR=0.54;95%CI=0.33 to 0.86,P=0.01 for TACE).The death rates in the IFN group also significantly decreased according to not only total events analysis(OR=0.42;95%CI=0.32 to 0.56;P<0.01)but also subgroup analysis(OR=0.51;95%CI=0.36 to 0.72;P=0.0002 for surgical resection;and OR=0.33;95%CI=0.21 to 0.50;P<0.01 for TACE).Conclusion Adjuvant IFN therapy may significantly reduce the recurrence rates of patients with viral hepatitis-related HCC and improve the survival of patients after surgical resection or TACE.The ideal dose mostly selected is 3 MIU/mL,three times per week,which can make patients tolerate the adverse reactions of IFN better and maintain effective concentrations for a long time.

Endoscopic Management of Upper Urinary Tract Urothelial Carcinoma

Upper urinary tract urothelial carcinoma (UTUC) is relatively uncommon. Radical nephroureterectomy with an ipsilateral bladder cuff excision has been the gold standard treatment for UTUC. However, recent advances in technology have made possible the increased use of endoscopic management for the treatment of UTUC. The definitive goal of endoscopic management of UTUC is cancer control while maintaining renal function and the integrity of the urinary tract. Endoscopic management includes both the retrograde ureteroscopic and antegrade percutaneous approaches. The endoscopic management of UTUC is a reasonable alternative for patients with renal insufficiency or a solitary functional kidney, bilateral disease, or a significant comorbidity that precludes radical surgery. Select patients with a functional contralateral kidney who have low-grade, low-stage tumors may also be candidates for endoscopic management. The careful selection of patients is the most important point for the successful endoscopic management of UTUC. It is crucial that patients are compliant and motivated, because a lifetime protocol of strict surveillance is necessary. Adjuvant topical therapy with Bacillus Calmette-Guerin or mitomycin C can be used after endoscopic management of UTUC in an attempt to reduce recurrence. In this article, we review current endoscopic techniques, indications for endoscopic treatment, clinical outcomes of endoscopic management, adjuvant topical therapy, and surveillance in patients with UTUC.

Tratamento adjuvante nos GISTs / Adjuvant treatment in GISTs

INTRODUÇÃO: O tumor estromal gastrointestinal (GIST) é o sarcoma mais comum do aparelho digestivo. Essa neoplasia ocorre devido à mutação do gene KIT com consequente ativação constitutiva da proteína KIT. O tratamento primário é cirúrgico e consiste na sua ressecção completa. Entretanto, alguns grupos de pacientes apresentam risco elevado de recorrência mesmo após operação com ressecção completa (R0), indicando diferenças no comportamento biológico. Estudos clínicos comprovaram a atividade clínica do mesilato de imatinibe, fazendo dele a primeira linha de tratamento padrão nos GISTs metastáticos ou irressecáveis, mudando muito o desfecho clínico dessa doença em relação aos benefícios anteriormente obtidos com a quimioterapia antineoplásica. MÉTODO: Foi realizada revisão da literatura com consulta nos periódicos das bases Medline/Pubmed, Scielo e Lilacs cruzando os descritores: tumor estromal gastrointestinal, Gist, tratamento, adjuvância. Além desta revisão foi adicionada a experiência pessoal dos autores. CONCLUSÃO: Melhor refinamento dos critérios de prognóstico tem permitido selecionar de forma mais adequada pacientes para o tratamento adjuvante com imatinibe. Os resultados de maior evidência até o momento respaldam o tratamento adjuvante por um ano, o que produz benefício significativo na sobrevida livre de recidiva, mas não na sobrevida global desses pacientes.

INTRODUCTION: Gastrointestinal stromal tumor (GIST) is the most common sarcoma of the digestive tract. This cancer occurs due to mutation of the KIT gene resulting in constitutive activation of KIT protein. The primary treatment is surgical and consists of complete resection. However, some groups of patients at high risk of recurrence even after surgery with complete resection (R0), indicate differences in biological behavior. Clinical studies have demonstrated the clinical activity of imatinib mesylate, making it the standard first-line treatment in metastatic or unresectable GISTs, changing the outcome of this disease in relation to the benefits obtained previously with cancer chemotherapy. METHODS: Was performed a literature review with consultation in Medline/Pubmed, Lilacs and Scielo crossing the key words: gastrointestinal stromal tumor, GIST, treatment, adjuvant treatment. In addition to this review was added to the authors' personal experience. CONCLUSION: Better refinement of prognostic criteria is allowed to select the most appropriate patients for adjuvant treatment with imatinib. The results are yet evident on basis of one year, which produces significant benefit in relapse-free survival but not overall survival in these patients.

Microcirurgia endoscópica transanal e tratamento adjuvante no câncer retal precoce / Transanal endoscopic microsurgery and adjuvant therapy in the treatment of early rectal cancer

RACIONAL: A excisão total do mesorreto é considerada a operação padrão no tratamento dos tumores do reto, apesar de não existir comprovação científica de que ela deva ser usada para todos os estádios da doença. Tem sido demonstrado que em casos escolhidos de tumores retais, resultados promissores podem ser conseguidos com tratamento local por microcirurgia endoscópica transanal. Tais tumores, denominados de câncer retal precoce, são tumores T1 - menores do que 4 cm -, bem diferenciados sem invasão angiolinfática pT1 Sm1. Como o risco de comprometimento linfonodal nesses tumores é de aproximadamente 3 por cento, a ressecção local teria grande chance de ser curativa. OBJETIVO: Apresentar os resultados de uma série prospectiva não randômica de pacientes portadores de câncer retal precoce submetidos ao tratamento local por microcirurgia endoscópica transanal. MÉTODOS: Entre 2002 e 2010, 38 pacientes avaliados por protocolo pré-operatório como portadores câncer retal precoce foram submetidos à ressecção local endoscópica microcirúrgica de toda a parede retal com o tumor quando localizado entre 2 e 8 cm da linha pectínea. A avaliação pré-operatória consistiu de toque retal, retossigmoidoscopia rígida para macrobiópsias, enema opaco e/ou colonoscopia, ultrassonografia endoretal e abdominal, tomografia axial computadorizada do abdome, radiografia do tórax e dosagem sérica do CEA. Realizou-se seguimento pós-operatório endoscópico e ultrassonográfico endoretal a cada três meses nos dois primeiros anos, e a cada seis nos próximos três anos, além de dosagem do CEA a cada seis meses nesse mesmo período de cinco anos. Avaliou-se a recidiva tumoral, morbidade e mortalidade. RESULTADOS: Após avaliação anatomopatológica da lesão, 29 cânceres retais precoces foram categorizados como de baixo risco e nove sendo de alto. O seguimento na série variou de um a sete anos. Recidiva tumoral foi confirmada em dois casos dos 38 (5,26 por cento), uma lesão considerada de alto...

BACKGROUND: The total mesorectal excision is considered the standard operation in the treatment of rectal tumors, although there is no scientific proof that it should be used for all stages of the disease. It has been demonstrated that in selected cases of rectal tumors, promising results can be achieved with local treatment by transanal endoscopic microsurgery. These tumors, called early rectal cancer, T1 tumors, are less than 4 cm, well differentiated without angiolymphatic invasion - pT1 SM1. As the risk of lymph node involvement in these tumors is approximately 3 percent, local resection would have a great chance to be curative. AIM: To present the results of a non-random prospective series of patients with early rectal cancer treated by transanal endoscopic microsurgery. METHODS: Between 2002 and 2010, 38 patients evaluated by preoperative protocol as patients with early rectal cancer underwent endoscopic microsurgical resection of the entire rectal wall including the tumor when located between 2 and 8 cm from the dentate line. The preoperative evaluation consisted of digital rectal examination, rigid sigmoidoscopy macrobiopsies, barium enema and/or colonoscopy, endorectal ultrasound and abdominal computed tomography of the abdomen, chest radiography and serum CEA. Was conducted follow-up with endoscopy and endorectal ultrasound every three months during the first two years, and every six in the next three years, and CEA every six months during the same period of five years. Was evaluated the tumor recurrence, morbidity and mortality. RESULTS: Pathologic evaluation considered 29 categorized as low risk and nine being high. The follow-up in the series ranged from one to seven years. Tumor recurrence was confirmed in two of the 38 cases (5.26 percent), in one the lesion was considered high and another low risk. CONCLUSION: Transanal endoscopic microsurgery associated or not to adjuvant therapy, may be, currently, considered the gold standard in...